FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4298087966> ?p ?o ?g. }

• W4298087966 endingPage "3" @default.
• W4298087966 startingPage "2" @default.
• W4298087966 abstract "In this issue of the Journal of Internal Medicine, Liu et al. [1] report that plasma levels of trimethylamine N-oxide (TMAO)—but not plasma levels of its metabolic precursors choline, carnitine, betaine, and trimethyl lysine—were associated with the risk of stroke. From a community-based cohort of 16,113 persons recruited from 2013 to 2018, the authors identified 412 cases of first stroke (321 ischemic and 91 non-ischemic) over a median follow-up of 5.3 years and compared them with 412 controls matched for age and sex. The odds ratio for ischemic stroke, for the highest versus lowest quartile of TMAO, was 1.81 (95% CI: 1.14–2.86, p = 0.020). The role of the intestinal microbiome in human disease has been of increasing interest in recent years. The best known of the toxic metabolites of the intestinal microbiome is TMAO, but there are a number of other toxic metabolites, including p-cresyl sulfate, p-cresyl glucuronide, and phenylacetylglutamine. Plasma levels of TMAO and these three other metabolites were significantly higher among patients with severe atherosclerosis not explained by traditional risk factors (“unexplained atherosclerosis”), compared to patients with a “protected” phenotype (little or no carotid plaque burden despite high levels of coronary risk factors) [2]. In linear regression, both TMAO and p-cresylsulfate were independent predictors of carotid plaque burden [2]. Trimethylamine is formed by intestinal bacteria from precursors such as carnitine (mainly from red meat) and phosphatidylcholine (from egg yolk and other sources) by the action of bacterial trimethylamine lyase (TMA lyase). Trimethylamine is then oxidized in the liver by flavin-containing monooxygenase 3 (FMO3). The role of the intestinal microbiome in the findings of Liu et al. [1] is revealed by their finding that high levels of plasma TMAO, but not of its metabolic precursors, were associated with stroke risk. TMAO causes atherosclerosis in a murine model [3]. Among more than 4000 patients referred for coronary angiography, TMAO levels in the top quartile were associated with a 2.5-fold increase in the risk of myocardial infarction, stroke, or vascular death over 3 years [4]. In patients with kidney disease, TMAO accelerates the decline of renal function and increases mortality [5]. Thus, it is no surprise that it would be associated with an increased risk of stroke. It should be noted, however, that high levels of TMAO are probably a marker for high plasma levels of other toxic metabolites of the intestinal microbiome, as even modest impairment of renal function—to an estimated glomerular filtration rate < 66 ml/min/1.73 m2, a normal level for people aged ≥70 years—is associated with significantly increased plasma levels of all seven metabolites assayed in our study of unexplained atherosclerosis [6]. TMAO levels can be reduced by diet—particularly by avoiding red meat [7] and egg yolk—and there are treatments in development to block both TMA lyase and FMO3. However, blocking the effects of TMAO will not prevent the adverse effects of the other toxic intestinal metabolites. Most of them are produced from amino acids found mainly in meat, so a vegetarian diet would reduce levels of most of those metabolites. Among patients with renal failure, renal transplantation or more intensive dialysis could reduce plasma levels of all the toxic intestinal metabolites [8]. Another approach that is being tested is fecal microbial transplantation; in a mouse model, this was shown to ameliorate atherosclerosis [9]. One lesson from the study of Liu et al. [1] is that people with renal impairment—including the elderly—should avoid red meat and egg yolk, and limit their intake of animal flesh [10]. The author declares no conflict of interest." @default.
• W4298087966 created "2022-10-01" @default.
• W4298087966 creator A5016780725 @default.
• W4298087966 date "2022-09-30" @default.
• W4298087966 modified "2023-09-26" @default.
• W4298087966 title "Cardiovascular effects of TMAO and other toxic metabolites of the intestinal microbiome" @default.
• W4298087966 cites W2115944543 @default.
• W4298087966 cites W2150350691 @default.
• W4298087966 cites W2162078360 @default.
• W4298087966 cites W2799619230 @default.
• W4298087966 cites W2886853362 @default.
• W4298087966 cites W2904124435 @default.
• W4298087966 cites W3100288551 @default.
• W4298087966 cites W4210336664 @default.
• W4298087966 cites W4298326331 @default.
• W4298087966 cites W4302292682 @default.
• W4298087966 doi "https://doi.org/10.1111/joim.13571" @default.
• W4298087966 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36177987" @default.
• W4298087966 hasPublicationYear "2022" @default.
• W4298087966 type Work @default.
• W4298087966 citedByCount "0" @default.
• W4298087966 crossrefType "journal-article" @default.
• W4298087966 hasAuthorship W4298087966A5016780725 @default.
• W4298087966 hasBestOaLocation W42980879661 @default.
• W4298087966 hasConcept C126322002 @default.
• W4298087966 hasConcept C127413603 @default.
• W4298087966 hasConcept C134018914 @default.
• W4298087966 hasConcept C143121216 @default.
• W4298087966 hasConcept C156957248 @default.
• W4298087966 hasConcept C2776149385 @default.
• W4298087966 hasConcept C2778435403 @default.
• W4298087966 hasConcept C2779896295 @default.
• W4298087966 hasConcept C2780645631 @default.
• W4298087966 hasConcept C2780924926 @default.
• W4298087966 hasConcept C2781123555 @default.
• W4298087966 hasConcept C42407357 @default.
• W4298087966 hasConcept C55493867 @default.
• W4298087966 hasConcept C60644358 @default.
• W4298087966 hasConcept C71924100 @default.
• W4298087966 hasConcept C78519656 @default.
• W4298087966 hasConcept C86803240 @default.
• W4298087966 hasConcept C90924648 @default.
• W4298087966 hasConceptScore W4298087966C126322002 @default.
• W4298087966 hasConceptScore W4298087966C127413603 @default.
• W4298087966 hasConceptScore W4298087966C134018914 @default.
• W4298087966 hasConceptScore W4298087966C143121216 @default.
• W4298087966 hasConceptScore W4298087966C156957248 @default.
• W4298087966 hasConceptScore W4298087966C2776149385 @default.
• W4298087966 hasConceptScore W4298087966C2778435403 @default.
• W4298087966 hasConceptScore W4298087966C2779896295 @default.
• W4298087966 hasConceptScore W4298087966C2780645631 @default.
• W4298087966 hasConceptScore W4298087966C2780924926 @default.
• W4298087966 hasConceptScore W4298087966C2781123555 @default.
• W4298087966 hasConceptScore W4298087966C42407357 @default.
• W4298087966 hasConceptScore W4298087966C55493867 @default.
• W4298087966 hasConceptScore W4298087966C60644358 @default.
• W4298087966 hasConceptScore W4298087966C71924100 @default.
• W4298087966 hasConceptScore W4298087966C78519656 @default.
• W4298087966 hasConceptScore W4298087966C86803240 @default.
• W4298087966 hasConceptScore W4298087966C90924648 @default.
• W4298087966 hasIssue "1" @default.
• W4298087966 hasLocation W42980879661 @default.
• W4298087966 hasLocation W42980879662 @default.
• W4298087966 hasOpenAccess W4298087966 @default.
• W4298087966 hasPrimaryLocation W42980879661 @default.
• W4298087966 hasRelatedWork W2014242281 @default.
• W4298087966 hasRelatedWork W2553125940 @default.
• W4298087966 hasRelatedWork W2751420116 @default.
• W4298087966 hasRelatedWork W3038079681 @default.
• W4298087966 hasRelatedWork W3087191973 @default.
• W4298087966 hasRelatedWork W3158847163 @default.
• W4298087966 hasRelatedWork W3185294159 @default.
• W4298087966 hasRelatedWork W4293579038 @default.
• W4298087966 hasRelatedWork W4300090893 @default.
• W4298087966 hasRelatedWork W1527921949 @default.
• W4298087966 hasVolume "293" @default.
• W4298087966 isParatext "false" @default.
• W4298087966 isRetracted "false" @default.
• W4298087966 workType "article" @default.